Genfit SA (GNFT)
3.76
+0.02
(+0.53%)
USD |
NASDAQ |
May 10, 16:00
Genfit Max Drawdown (5Y): 88.42% for April 30, 2024
Max Drawdown (5Y) Chart
Historical Max Drawdown (5Y) Data
Date | Value |
---|---|
April 30, 2024 | 88.42% |
March 31, 2024 | 88.42% |
February 29, 2024 | 88.42% |
January 31, 2024 | 88.42% |
December 31, 2023 | 88.42% |
November 30, 2023 | 88.42% |
October 31, 2023 | 88.42% |
September 30, 2023 | 88.27% |
August 31, 2023 | 88.27% |
July 31, 2023 | 88.27% |
June 30, 2023 | 88.27% |
May 31, 2023 | 88.27% |
April 30, 2023 | 88.27% |
March 31, 2023 | 88.27% |
February 28, 2023 | 88.27% |
January 31, 2023 | 88.27% |
December 31, 2022 | 88.27% |
November 30, 2022 | 88.27% |
October 31, 2022 | 88.27% |
September 30, 2022 | 88.27% |
August 31, 2022 | 88.27% |
July 31, 2022 | 88.27% |
June 30, 2022 | 88.27% |
May 31, 2022 | 88.27% |
April 30, 2022 | 88.27% |
Date | Value |
---|---|
March 31, 2022 | 88.27% |
February 28, 2022 | 88.27% |
January 31, 2022 | 88.27% |
December 31, 2021 | 88.27% |
November 30, 2021 | 87.52% |
October 31, 2021 | 86.55% |
September 30, 2021 | 86.04% |
August 31, 2021 | 86.04% |
July 31, 2021 | 86.04% |
June 30, 2021 | 85.85% |
May 31, 2021 | 85.85% |
April 30, 2021 | 85.85% |
March 31, 2021 | 85.85% |
February 28, 2021 | 85.85% |
January 31, 2021 | 85.85% |
December 31, 2020 | 85.85% |
November 30, 2020 | 85.85% |
October 31, 2020 | 85.85% |
September 30, 2020 | 85.69% |
August 31, 2020 | 81.33% |
July 31, 2020 | 81.33% |
June 30, 2020 | 79.73% |
May 31, 2020 | 79.65% |
April 30, 2020 | 57.31% |
March 31, 2020 | 57.31% |
Max Drawdown Definition
Max drawdown is an indicator of the risk of a portfolio chosen based on a certain strategy. It measures the largest single drop from peak to bottom in the value of a portfolio before a new peak is achieved.
Max Drawdown (5Y) Range, Past 5 Years
12.40%
Minimum
May 2019
88.42%
Maximum
Oct 2023
77.91%
Average
87.04%
Median
Max Drawdown (5Y) Benchmarks
Cellectis SA | 97.08% |
Biophytis SA | -- |
DBV Technologies SA | 97.67% |
Adaptimmune Therapeutics PLC | 96.57% |
Akari Therapeutics PLC | 98.58% |